We are live on ! Find out more
ALNA

Allena Pharmaceuticals

Delisted

ALNA was delisted on the 7th of September, 2022.

30 hedge funds and large institutions have $21.2M invested in Allena Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more capital invested

Capital invested by funds: $14M → $21.2M (+$7.2M)

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

3% more funds holding

Funds holding: 2930 (+1)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

22% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 9

Holders
30
Holders Change
+1
Holders Change %
+3.45%
% of All Funds
0.62%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
7
Increased
7
Reduced
9
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
SIM
26
Spark Investment Management
New York
$24K
Bank of America
27
Bank of America
North Carolina
$9K +$9.07K +5,400 New
Wells Fargo
28
Wells Fargo
California
$2K -$3.53K -2,100 -66%
BNP Paribas Financial Markets
29
BNP Paribas Financial Markets
France
$98
DVC
30
Deer VII & Co
New York
-$2.17M -2,263,365 Closed
SFM
31
Sphera Funds Management
Israel
-$643K -667,800 Closed
Millennium Management
32
Millennium Management
New York
-$358K -371,576 Closed
CHP
33
Cable Hill Partners
Oregon
-$13K -13,000 Closed
UBS Group
34
UBS Group
Switzerland
-$7K -7,757 Closed
Victory Capital Management
35
Victory Capital Management
Texas
-$4K -4,682 Closed
S
36
SignatureFD
Georgia
-$2.18K -1,300 -87%

ALNA Hedge Fund Activity: Q2 2020 in Review

30 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Allena Pharmaceuticals (ALNA) for Q2 2020, worth a combined $21.2M — up 52% from $14M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ALNA positions and 6 closed out — a net gain of 1 holder — while 7 added to existing stakes and 9 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $2.57M. The largest seller was Deer VII & Co, exiting entirely with an estimated $2.17M sold.

  • 30 institutional investors held Allena Pharmaceuticals (ALNA) as of Q2 2020, up from 29 in Q1 2020.
  • Funds reported $21.2M of Allena Pharmaceuticals stock for Q2 2020, up 52% quarter-over-quarter.
  • 7 funds opened new Allena Pharmaceuticals positions in Q2 2020 and 6 closed out, a net change of +1 holder.
  • The largest Allena Pharmaceuticals buyer in Q2 2020 was Sabby Management, an estimated $2.57M added.
  • The largest Allena Pharmaceuticals seller in Q2 2020 was Deer VII & Co, an estimated $2.17M sold.

Based on aggregated 13F filings for Q2 2020.